You are here: Industry Insights > gastric cancer

News List

Enhertu granted orphan drug designation in US for gastric cancer pharmaceutical-business-review
May 28, 2020
AstraZeneca and Daiichi Sankyo Company, Limited (Daiichi Sankyo)’s Enhertu (trastuzumab deruxtecan) has been granted Orphan Drug Designation (ODD) in the US for the treatment of patients with gastric cancer, including gastroesophageal junction cancer.
AstraZeneca, Daiichi Sankyo get FDA breakthrough therapy status for gastric cancer drug pharmaceutical-business-review
May 12, 2020
AstraZeneca and Daiichi Sankyo have secured breakthrough therapy designation from the US Food and Drug Administration (FDA) for its Enhertu.
Incidence of Early-Onset Gastric Cancer Increasing in the U.S. drugs
January 02, 2020
The incidence of early-onset gastric cancer has been increasing in the United States, and it seems to be distinct clinically and genetically from late-onset gastric cancer ...
Merck and Pfizer Provide Update on Phase III JAVELIN Gastric 100 Trial En-CPhI.CN
November 11, 2019
Merck and Pfizer Inc. announced topline results of the Phase III JAVELIN Gastric 100 study evaluating avelumab as first-line maintenance therapy following induction chemotherapy in patients with unresectable ...
Imugene ‘encouraged’ by data for HER2 vaccine in gastric cancer fiercebiotech
December 26, 2018
Australian biotech Imugene says its HER2 vaccine hit the mark in a phase 1b trial, setting up a phase 2 study that will start recruiting patients in the new year.....
Lilly’s Cyramza fails to improve overall survival in gastric cancer pharmatimes
December 12, 2017
Eli Lilly’s Cyramza has hit its primary goal in a late-stage study showing extended progression-free survival in patients with gastric cancer, but the drug failed to improve overall survival, a secondary endpoint.
Japan approves Opdivo, the first-ever immuno-oncology agent for unresectable advanced/recurrent gast pharmaasia
September 27, 2017
Opdivo is the first and only immuno-oncology treatment to demonstrate survival benefit in patients who underwent two or more prior treatments.
A*STAR scientists’ discovery on Gastric Cancer pharmaasia
June 14, 2017
Scientists from A*STAR’s Institute of Medical Biology (IMB) have discovered gastric cancer is driven by Lgr5-expressing chief cells, a discovery that represents a significant breakthrough in the study of cancer biology...
Opdivo demonstrated efficacy and improved survival in patients with previously treated advanced gast cphi-online
January 20, 2017
Opdivo demonstrated a 37% reduction in the risk of death compared to placebo.

Previous page 1 2 Next page